Baskar Subramani
Baskar Subramani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Farah Dalila Binti Mohd Zain
2 shared publicationsGounder Sellamuthu Subbanna
2 shared publicationsNur Ezzati Izyan Binti Mohd Radzuanb
2 shared publicationsNurhidayah Bt Mohamad Sait
Minggu dan
2 shared publicationsSellamuthu Subbanna Gounder
Minggu dan
2 shared publications- Abhi Veerakumarasivam
Medical Genetics Laboratory, Genetics and Regenerative Medicine Research Centre, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
1 shared publication
Latest Publications
- Open Access
- 31 January 2022
- Published by Penerbit Universiti Kebangsaan Malaysia (UKM Press) in Sains Malaysiana
- Vol. 51 (1) , 271-284
A Safety Evaluation of Intravenous Administration of ex vivo Expanded Human Peripheral Blood-Derived NK Cells: A Preclinical Study
- 31 January 2022
- Published by Penerbit Universiti Kebangsaan Malaysia (UKM Press) in Sains Malaysiana
- Vol. 51 (1) , 271-284
Open AccessA Safety Evaluation of Intravenous Administration of ex vivo Expanded Human Peripheral Blood-Derived NK Cells: A Preclinical Study
- Open Access
- 12 April 2019
- Published by ClinMed International Library in International Journal of Critical Care and Emergency Medicine
- Vol. 5 (2)
Enhancement of NK Cell Cytotoxicity against MDA-MB-231 Cell by Presence of OK432
Several advancements are made in the field of immunotherapy for enabling an effective cure for cancer. Treatments are being approached with multipronged approach with combination therapies as well as by gene therapy. Cancer incidence however progressing further mainly due to the changes in lifestyle. Epidemiological surveys indicate that cancer incidence is being more predominant in females; in particularly breast cancer is the most common diseases throughout world. However, the treatments attempted to deal with breast cancers especially triple negative cancer hasn't shown considerable success.
- 12 April 2019
- Published by ClinMed International Library in International Journal of Critical Care and Emergency Medicine
- Vol. 5 (2)
Open AccessEnhancement of NK Cell Cytotoxicity against MDA-MB-231 Cell by Presence of OK432
Several advancements are made in the field of immunotherapy for enabling an effective cure for cancer. Treatments are being approached with multipronged approach with combination therapies as well as by gene therapy. Cancer incidence however progressing further mainly due to the changes in lifestyle. Epidemiological surveys indicate that cancer incidence is being more predominant in females; in particularly breast cancer is the most common diseases throughout world. However, the treatments attempted to deal with breast cancers especially triple negative cancer hasn't shown considerable success.
- Open Access
- 2 August 2018
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2018, 1-6
Effect of Aging on NK Cell Population and Their Proliferation at Ex Vivo Culture Condition
Age-associated changes in natural killer (NK) cell population, phenotype, and functions are directly attributed to the risk of several diseases and infections. It is predicted to be the major cause of the increase in mortality. Based on the surface density of CD56, NK cells are subdivided into two types, such as CD56brightand CD56dimcells, which represent cytokine production and cytotoxicity. In our study, we have examined the age-associated changes in the NK cell population and their subsets at different age groups of males and females (at a range from 41 to 80 years). We found that the total lymphocyte count significantly dropped upon aging in both genders. Although, the level of total immune cells also dropped on aging, and surprisingly the total NK cell population was remarkably increased with the majority of NK cells being CD56dim. Subsequently, we evaluated the proliferation potential of NK cells and our results showed that the NK cell proliferation ability declines with age. Overall, our findings prove that there is an increase in the circulating NK cell population upon aging. However, the proliferation rate upon aging declines when compared to the young age group (<41 yrs).
- 2 August 2018
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2018, 1-6
Open AccessEffect of Aging on NK Cell Population and Their Proliferation at Ex Vivo Culture Condition
Age-associated changes in natural killer (NK) cell population, phenotype, and functions are directly attributed to the risk of several diseases and infections. It is predicted to be the major cause of the increase in mortality. Based on the surface density of CD56, NK cells are subdivided into two types, such as CD56brightand CD56dimcells, which represent cytokine production and cytotoxicity. In our study, we have examined the age-associated changes in the NK cell population and their subsets at different age groups of males and females (at a range from 41 to 80 years). We found that the total lymphocyte count significantly dropped upon aging in both genders. Although, the level of total immune cells also dropped on aging, and surprisingly the total NK cell population was remarkably increased with the majority of NK cells being CD56dim. Subsequently, we evaluated the proliferation potential of NK cells and our results showed that the NK cell proliferation ability declines with age. Overall, our findings prove that there is an increase in the circulating NK cell population upon aging. However, the proliferation rate upon aging declines when compared to the young age group (<41 yrs).
- Open Access
- 31 December 2017
- Published by ClinMed International Library in International Journal of Stem cell Research & Therapy
- Vol. 4 (2)
Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives
Liver cirrhosis is a leading cause of mortality worldwide. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation.
- 31 December 2017
- Published by ClinMed International Library in International Journal of Stem cell Research & Therapy
- Vol. 4 (2)
Open AccessAdult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives
Liver cirrhosis is a leading cause of mortality worldwide. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation.
- Open Access
- 12 March 2013
- Published by Spandidos Publications in Oncology Letters
- Vol. 5 (5) , 1611-1614
Autologous immune enhancement therapy: A case report of a stage IV colonic cancer
Current modalities of cancer treatment, including surgery, chemotherapy and radiotherapy, show marginal therapeutic responses in cancer patients. In adoptive immunotherapy, interleukin-2 (IL-2) activated immune cells demonstrated notable results in patients with advanced malignant disease. The present study reports the efficacy and safety of repetitive infusions of autologous immune enhancement therapy (AIET) in a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. Peripheral blood was aspirated from the patient. Specifically, natural killer (NK) cells and T-lymphocytes were isolated from the peripheral blood mononuclear cells (PBMCs). These cells were activated and expanded ex vivo for 14 days and were transfused intravenously to the patient. After six infusions of AIET, the carcinoembryonic antigen (CEA) level was decreased from 901 to 437 U/ml, regression of lesions was noted and there were no adverse reactions during the course of this therapy. Thus, AIET may be a promising anticancer approach to eradicate tumor cells with other conventional therapies.
- 12 March 2013
- Published by Spandidos Publications in Oncology Letters
- Vol. 5 (5) , 1611-1614
Open AccessAutologous immune enhancement therapy: A case report of a stage IV colonic cancer
Current modalities of cancer treatment, including surgery, chemotherapy and radiotherapy, show marginal therapeutic responses in cancer patients. In adoptive immunotherapy, interleukin-2 (IL-2) activated immune cells demonstrated notable results in patients with advanced malignant disease. The present study reports the efficacy and safety of repetitive infusions of autologous immune enhancement therapy (AIET) in a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. Peripheral blood was aspirated from the patient. Specifically, natural killer (NK) cells and T-lymphocytes were isolated from the peripheral blood mononuclear cells (PBMCs). These cells were activated and expanded ex vivo for 14 days and were transfused intravenously to the patient. After six infusions of AIET, the carcinoembryonic antigen (CEA) level was decreased from 901 to 437 U/ml, regression of lesions was noted and there were no adverse reactions during the course of this therapy. Thus, AIET may be a promising anticancer approach to eradicate tumor cells with other conventional therapies.